APPENDIX A: Pending Claims of Application Serial No. 10/267,476

Listing of Claims:

Claim 1-20 (canceled).

Claim 21 (currently amended): An isolated protein complex comprising a first protein interacting with a second protein, wherein said first protein is chosen from:

- (a) FIBP (SEQ ID NO:1), or a fragment thereof that interacts with PIP5K2B (SEQ ID NO:2);
- (b) a first polypeptide having an amino acid sequence at least 75% identical to that of (a), and that interacts with PIP5K2B (SEQ ID NO:2); and
- (c) a first fusion protein comprising (a) or (b); and wherein said second protein is selected from the group consisting of:
 - (i) PIP5K2B (SEQ ID NO:2), or a fragment thereof that interacts with FIBP (SEQ ID NO:1);
 - (ii) a second polypeptide having an amino acid sequence at least 75% identical to that of (i), and that interacts with FIBP (SEQ ID NO:1); and
 - (iii) a second fusion protein comprising (i) or (ii).

Claim 22 (currently amended): The isolated protein complex of Claim 21, wherein said first protein is FIBP (SEQ ID NO:1).

Claim 23 (currently amended): The isolated protein complex of Claim 21, wherein said second protein is PIP5K2B (SEQ ID NO:2).

Claim 24 (currently amended): The isolated protein complex of Claim 21, wherein said first protein comprises an amino acid sequence that is at least 80% identical to <u>SEQ</u>

<u>ID NO:1</u> the amino acid sequence of FIBP under GenBank Accession No. AF010187 as

of October 9, 2001, and wherein said first protein interacts with PIP5K2B (SEQ ID NO:2).

Claim 25 (currently amended): The isolated protein complex of Claim 21, wherein said first protein comprises an amino acid sequence that is at least 90% identical to <u>SEQ ID NO:1</u> the amino acid sequence of FIBP under GenBank Accession No. AF010187 as of October 9, 2001, and wherein said first protein interacts with PIP5K2B (<u>SEQ ID NO:2</u>).

Claim 26 (currently amended): The isolated protein complex of Claim 21, wherein said first protein comprises a contiguous span of at least 10 amino acids of FIBP (SEQ ID NO:1), and wherein said first protein interacts with PIP5K2B (SEQ ID NO:2).

Claim 27 (currently amended): The isolated protein complex of Claim 21, wherein said second protein comprises an amino acid sequence that is at least 80% identical to amino acid residues 21 to 223 of PIP5K2B (SEQ ID NO:2), and wherein said second protein interacts with FIBP (SEQ ID NO:1).

Claim 28 (currently amended): The isolated protein complex of Claim 21, wherein said second protein comprises an amino acid sequence that is at least 90% identical to the amino acid residues 21 to 223 of PIP5K2B (SEQ ID NO:2), and wherein said second protein interacts with FIBP (SEQ ID NO:1).

Claim 29 (currently amended): The isolated protein complex of Claim 21, wherein said second protein comprises the amino acid residues 21 to 223 of PIP5K2B (SEQ ID NO:2), or an amino acid sequence that is at least 95% identical to the amino acid residues 21 to 223 of PIP5K2B (SEQ ID NO:2), and wherein said second protein interacts with FIBP (SEQ ID NO:1).

Claim 30 (currently amended): The isolated protein complex of elaim Claim 21, wherein said first protein is said first fusion protein, and said second protein is said second fusion protein, wherein at least one of said first and second fusion proteins comprises a detectable tag.

Claim 31 (currently amended): A method for selecting modulators of the isolated protein complex of claim Claim 21, said method comprising:

contacting said first protein with said second protein in the presence of one or more test compounds; and

detecting the interaction between said first protein and said second protein.

Claim 32 (currently amended): The method of elaim Claim 31, wherein said first protein is said first fusion protein, or said second proteins is said second fusion protein, or both, at least one of said first and second fusion proteins having a detectable tag.

Claim 33 (currently amended): The method of claim Claim 31, wherein said contacting step is conducted *in vitro*.

Claim 34 (currently amended): The method of elaim Claim 31, wherein the interaction between said first protein and said second protein is determined in a host cell.

Claim 35 (currently amended): The method of elaim Claim 34, wherein said host cell is a yeast cell.

Claim 36 (currently amended): The method of elaim Claim 31, further comprising contacting said first protein with said second protein in the absence of said one or more test compounds and detecting the interaction between said first protein and said second protein, wherein a difference between the interaction detected in the presence and absence of said one or more test compounds indicates that said one or more test compounds can modulate said interaction.

Claim 37 (currently amended): The method of elaim Claim 36, further comprising a step of generating a data set defining one or more selected test compounds, said data set being embodied in a transmittable form.

Claim 38 (currently amended): The method of elaim Claim 31, wherein one of said first and second proteins is immobilized on a solid support and the interaction is detected as binding between said first and second proteins on said solid support.

Claim 39 (previously presented): The method of Claim 31, wherein said first protein is said first fusion protein and said second protein is said second fusion protein;

wherein one of said first and second fusion proteins comprises a DNA binding domain while the other of said first and second fusion proteins comprises a transcription-activating domain;

wherein said first and second fusion proteins are expressed in a host cell that contains a reporter gene;

wherein the transcription of said reporter gene is controlled by the interaction between the first fusion protein and the second fusion protein; and

wherein said step of detecting the interaction between said first protein and said second protein comprises determining the expression of said reporter gene in said host cell.